ArticleEpilepsy currents2026
Is It Policy And Not Treatment That Actually Determines Epilepsy Outcomes?
Article in Epilepsy currents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is among the most prevalent and treatable neurological disorders worldwide, yet it remains associated with persistent and preventable inequities in morbidity and mortality. Despite major advances in diagnostics, pharmacotherapy, and surgery, substantial treatment gaps and excess mortality persist globally across all income segments of society. These outcomes frequently reflect failures of access, continuity, and health-system design, rather than limitations of existing therapies. Using epilepsy specifically as a tracer neurological condition, this analysis examines how health systems respond to chronic neurological disease under stress. In many low- and middle-income countries and other underserved settings, health systems have evolved passively, shaped by fragmented financing, short-term priorities, and misaligned incentives rather than by intentional, outcome-oriented policy. Evidence from global neurology and health economics shows that such passive system development produces reactive care models, inefficient resource use, and high indirect costs due to productivity loss, caregiver burden, injury, disability, and premature mortality. Environmental and climate-related stressors further expose these structural weaknesses in vulnerable regions. Extreme weather events, environmental instability, and displacement disrupt medication supply, infrastructure, and continuity of neurological care. In epilepsy, even brief interruptions in treatment can precipitate breakthrough seizures, injury, or death, transforming environmental exposure into avoidable neurological harm. This article contends that policy is the primary determinant of whether health systems remain reactive or become resilient. Secondly, we propose that artificial intelligence (AI) may play a critical enabling role by supporting the development of context-appropriate policy and system design. When aligned with local realities, AI-facilitated policy could enable earlier diagnosis, sustained treatment, and more efficient resource allocation. Proactive epilepsy care is therefore not only an ethical imperative but an economically rational strategy. Aligning policy, technology, and health system design is essential to deliver durable, equitable, and cost-effective epilepsy care in an era of accelerating environmental and geopolitical change where external funding is diminishing globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.